# A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer

> **NCT04324476** · PHASE2 · UNKNOWN · sponsor: **Jiangsu Cancer Institute & Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Advanced Colorectal Cancer

## Interventions

- **DRUG:** Bevacizumab、Oxaliplatin、Irinotecan、Capecitabine

## Key facts

- **NCT ID:** NCT04324476
- **Lead sponsor:** Jiangsu Cancer Institute & Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-01
- **Primary completion:** 2022-07
- **Final completion:** 2023-06
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2021-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04324476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04324476, "A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04324476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*